Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/04/25
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 AntibodyGlobeNewsWire • 11/04/25
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025GlobeNewsWire • 10/24/25
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 MillionGlobeNewsWire • 10/15/25
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common StockGlobeNewsWire • 10/14/25
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsGlobeNewsWire • 10/13/25
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025GlobeNewsWire • 10/05/25
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation ForumGlobeNewsWire • 09/08/25
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/05/25
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardSeeking Alpha • 06/18/25
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 ReadoutsPRNewsWire • 06/17/25
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025PRNewsWire • 06/16/25
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should KnowZacks Investment Research • 05/30/25
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34%Zacks Investment Research • 05/13/25
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdatePRNewsWire • 05/08/25
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001PRNewsWire • 05/05/25
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 AntibodyPRNewsWire • 03/27/25
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdatePRNewsWire • 02/27/25
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis OrganisationPRNewsWire • 02/19/25
Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 02/10/25